Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
Cytokinetics, Incorporated's share was trading at $65.16 as of February 2nd. Copyright: nexusplexus / 123RF Stock Photo Cytokinetics (CYTK) is a late-stage biopharma focused on developing drugs that target the sarcomere, specifically cardiac myosin, to treat debilitating muscle diseases. Its pipeline is concentrated on three drugs addressing two primary disease areas: hypertrophic cardiomyopathy (HCM) and chronic heart failure (CHF), with distinct subtypes in each category. The lead investment thesis centers on Aficamten, a selective cardiac myosin inhibitor designed to “calm” overactive heart muscle, improving relaxation and reducing left ventricular outflow tract obstruction in obstructive HCM (oHCM). Clinical data from the SEQUOIA-HCM and MAPLE-HCM Phase III trials demonstrate that Aficamten significantly improves exercise capacity, outflow obstruction, and quality-of-life measures, while showing a strong safety profile and superior efficacy compared to the commonly prescribe
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
- Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]FOX Business Network
- Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.MarketBeat
- How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]Yahoo! Finance
- Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]USA TODAY
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 2/2/26 - Form 4
- 1/20/26 - Form 4
- 1/16/26 - Form 4
- CYTK's page on the SEC website